DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

Phase 1

Completed

Conditions: Endometriosis Related Pain
Overactive Bladder
Diabetic Neuropathic Pain
Refractory or Unexplained Chronic Cough

Interventions: Drug: BAY1817080

First Posted Date: 2020-07-15

Last Posted Date: 2024-03-26

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT04471337

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Phase 3

Recruiting

Conditions: Cancer

Interventions: Drug: Darolutamide (Nubeqa, BAY1841788)

First Posted Date: 2020-07-09

Last Posted Date: 2025-05-13

Lead Sponsor: Bayer

Target Recruit Count: 402

Registration Number: NCT04464226

Locations: 🇫🇷
Centre Jean Perrin, Clermont-ferrand, France
🇱🇻
P. Stradins Clinical University Hospital, Riga, Latvia
🇱🇻
Riga East Clinical University Hospital "Gailezers", Riga, Latvia

and more 368 locations

Study to Learn About the Effect of Elevit (a Food Supplement Containing Several Vitamins, Minerals, Lutein and DHA) on the Nutrient Content in the Breast Milk and Blood of Women During Breastfeeding Period and on Babies' Physical Growth Parameters

Not Applicable

Completed

Conditions: Healthy Lactating Mother

Interventions: Dietary Supplement: Elevit Breastfeeding & Postnatal Care
Drug: Placebo

First Posted Date: 2020-07-08

Last Posted Date: 2020-07-08

Lead Sponsor: Bayer

Target Recruit Count: 68

Registration Number: NCT04462939

Locations: 🇩🇪
Praxis Fr. Dr. K. Maar, Berlin, Germany
🇩🇪
Praxis Hr. E. Goeckeler-Leopold, Geseke, Nordrhein-Westfalen, Germany
🇩🇪
Gynäkologische Gemeinschaftspraxis Freising, Freising, Bayern, Germany

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: Damoctocog alfa pegol (Jivi, BAY94-9027)

First Posted Date: 2020-07-08

Last Posted Date: 2025-05-08

Lead Sponsor: Bayer

Target Recruit Count: 62

Registration Number: NCT04461639

Locations: 🇪🇸
Many Locations, Multiple Locations, Spain

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

Phase 1

Completed

Conditions: Overactive Bladder
Diabetic Neuropathic Pain
Refractory or Unexplained Chronic Cough
Endometriosis Related Pain

Interventions: Drug: BAY1817080
Drug: Midazolam

First Posted Date: 2020-07-01

Last Posted Date: 2023-01-20

Lead Sponsor: Bayer

Target Recruit Count: 37

Registration Number: NCT04454424

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Drug: LMWH and Phenprocoumon

First Posted Date: 2020-06-24

Last Posted Date: 2022-04-28

Lead Sponsor: Bayer

Target Recruit Count: 22153

Registration Number: NCT04444804

Locations: 🇩🇪
Multiple facilities, Multiple Locations, Germany

A Study Using the LMC Diabetes Registry to Learn More About Chronic Kidney Disease (CKD) in Canadian Patients With Type 2 Diabetes (T2D)

Completed

Conditions: Chronic Kidney Disease in Type 2 Diabetes

Interventions: Drug: The physician's prescription in routine clinical practice

First Posted Date: 2020-06-24

Last Posted Date: 2021-10-05

Lead Sponsor: Bayer

Target Recruit Count: 14873

Registration Number: NCT04445181

Locations: 🇨🇦
A Database, A Database, Canada

Clinical Study on the Effect of Elevit Pregnancy 2nd & 3rd Trimester (Multi-micronutrients & DHA Supplement) on the Nutritional Status of Pregnant Women During Second and Third Trimester

Not Applicable

Completed

Conditions: Healthy Pregnant Women

Interventions: Dietary Supplement: Elevit Pregnancy 2nd & 3rd Trimester
Other: Non-Supplement

First Posted Date: 2020-06-19

Last Posted Date: 2020-11-16

Lead Sponsor: Bayer

Target Recruit Count: 164

Registration Number: NCT04438928

Locations: 🇮🇹
ASST Fatebenefratelli Sacco, Milano, Lombardia, Italy

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Finerenone (BAY94-8862)
Other: Placebo

First Posted Date: 2020-06-17

Last Posted Date: 2024-07-03

Lead Sponsor: Bayer

Target Recruit Count: 6016

Registration Number: NCT04435626

Locations: 🇺🇸
Eastern Shore Research Institute, LLC | Fairhope, AL, Fairhope, Alabama, United States
🇺🇸
Mobile Heart Specialists, PC, Mobile, Alabama, United States
🇺🇸
Heart Clinic Arkansas, Little Rock, Arkansas, United States

and more 654 locations

Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants

Phase 1

Completed

Conditions: Endometriosis
Overactive Bladder
Cough

Interventions: Drug: BAY1817080
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2020-06-09

Last Posted Date: 2022-01-24

Lead Sponsor: Bayer

Target Recruit Count: 42

Registration Number: NCT04423744

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy